-
Product Insights
Hepatitis D – Drugs In Development, 2023
Global Markets Direct’s, ‘Hepatitis D - Drugs In Development, 2023’, provides an overview of the Hepatitis D pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hepatitis D, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
T-Cell Leukemia – Drugs In Development, 2023
Global Markets Direct’s, ‘T-Cell Leukemia - Drugs In Development, 2023’, provides an overview of the T-Cell Leukemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for T-Cell Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Leukocyte Disorders (White Blood Cell Disorders) – Drugs In Development, 2023
Global Markets Direct’s, ‘Leukocyte Disorders (White Blood Cell Disorders) - Drugs In Development, 2023’, provides an overview of the Leukocyte Disorders (White Blood Cell Disorders) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Leukocyte Disorders (White Blood Cell Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Anemia in Chronic Kidney Disease (Renal Anemia) – Drugs In Development, 2023
Global Markets Direct’s, ‘Anemia in Chronic Kidney Disease (Renal Anemia) - Drugs In Development, 2023’, provides an overview of the Anemia in Chronic Kidney Disease (Renal Anemia) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Anemia in Chronic Kidney Disease (Renal Anemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
Myelofibrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Myelofibrosis - Drugs In Development, 2023’, provides an overview of the Myelofibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myelofibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) – Drugs In Development, 2023
Global Markets Direct’s, ‘T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) - Drugs In Development, 2023’, provides an overview of the T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) pipeline landscape. The report provides comprehensive information on the therapeutics under development for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Drugs In Development, 2023’, provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
Hepatitis C – Drugs In Development, 2023
Global Markets Direct’s, ‘Hepatitis C - Drugs In Development, 2023’, provides an overview of the Hepatitis C pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hepatitis C, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Amlodipine in Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Amlodipine in Hypertension report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Amlodipine in Hypertension Drug Details: Amlodipine is under development for the treatment...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – JNJ-8780 in B-Cell Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - JNJ-8780 in B-Cell Non-Hodgkin Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. JNJ-8780 in B-Cell Non-Hodgkin Lymphoma Drug Details: JNJ-8780 is under development...